Avadel Pharmaceuticals plc AVDL
21.64 USD 0.00 (+0.00%)
Feb 13, 2026, 9:30 AM EST
21.64 Day range 21.64
52-week range unavailable
- YTD
- +0.42%
- 1 year
- +140.71%
- Market cap
- 2.12B
- Revenue (ttm)
- 248.52M
- Profit margin
- -0.11%
- Shares out
- 98.15M
- Forward P/E
- 27.74
- YTD return
- +0.42%
- 1-year return
- +140.71%
- Volume
- 35.02M
- Open
- 21.64
- Previous close
- 21.64
- Day's range
- 21.64 – 21.64
- Analysts
- Hold
- Price target
- 20.71 (-4.3%)
- Earnings date
- Mar 2, 2026
2Y +11.10 (+105.01%)
Key statistics
- Enterprise value
- 2.06B
- PEG ratio
- 0.00
- Price / sales
- 8.55
- Price / book
- 21.43
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 54.90%
- Free cash flow
- 2.73M
- Total cash
- 91.58M
- Total debt
- 37.38M
- Return on equity
- -0.32%
- Short % of float
- 2.38%
- 50-day average
- 21.52
- 200-day average
- 15.84
Analyst view
Consensus: hold
Hold
Price target (mean) 20.71 -4.3% downside
Now 21.64
- Target (low)
- 18.50
- Target (mean)
- 20.71
- Target (high)
- 23.00
Ratings (0m) 9 0 buy · 9 hold · 0 sell
- Strong buy0
- Buy0
- Hold9
- Sell0
- Strong sell0
Next earnings
Mar 2, 2026
Expected Mar 2, 2026. Consensus EPS estimate 0.14429.
Financials — quick view
AVDL Revenue — quarterly 77.47M
AVDL Net income — quarterly 20.00K
AVDL EPS — quarterly 0.00
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Mar 2, 2026 | Dec 1, 2025 | 0.08 | — | — | — |
| Nov 4, 2025 | Sep 1, 2025 | 0.04 | — | — | — |
| Aug 7, 2025 | Jun 1, 2025 | 0.02 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 20, 2025 | Wells Fargo | main | Equal-Weight | Equal-Weight |
| Nov 7, 2025 | Wells Fargo | main | Equal-Weight | Equal-Weight |
| Oct 28, 2025 | UBS | down | Buy | Neutral |
| Oct 23, 2025 | Leerink Partners | down | Outperform | Market Perform |
| Oct 23, 2025 | HC Wainwright & Co. | down | Buy | Neutral |
| Oct 22, 2025 | Jefferies | down | Buy | Hold |
About Avadel Pharmaceuticals plc
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is the LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of cataplexy or excessive daytime sleepiness in patients seven years of age and older with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin 2, Ireland. As of February 12, 2026, Avadel Pharmaceuticals plc operates as a subsidiary of Alkermes plc.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Country
- Ireland
- Website
- avadel.com
News
10 Health Care Stocks With Whale Alerts In Today's Session 
Legence, Cidara Therapeutics, Avadel Pharmaceuticals, Omeros And Other Big Stocks Moving Higher On Friday 
12 Health Care Stocks Moving In Friday's Pre-Market Session 
Tesla To Rally More Than 16%? Here Are 10 Top Analyst Forecasts For Thursday 
This Unisys Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday 
Earnings Scheduled For August 7, 2025 
Earnings Scheduled For May 7, 2025 
Earnings Scheduled For March 3, 2025 
Avadel Pharmaceuticals Misses Earnings Estimates But Posts 150% Sales Increase From Narcolepsy Drug LUMRYZ 
Earnings Scheduled For November 12, 2024
Your note
Sign in to keep a note on AVDL — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| AMIN NASEEM M.D. | Director | Stock Award(Grant) | Jul 28, 2025 | 22,000 |
| DIVIS GREGORY J. JR. | Chief Executive Officer | Stock Award(Grant) | Mar 4, 2025 | 221,100 |
| ENDE ERIC J | Director | Stock Award(Grant) | Jul 28, 2025 | 219,900 |
| GLASS GEOFFREY MICHAEL | Director | Stock Award(Grant) | Jul 28, 2025 | 166,979 |
| MCCAMISH MARK ANTHONY | Director | Stock Gift | Feb 3, 2026 | 0 |
| MCHUGH THOMAS S | Chief Financial Officer | Stock Award(Grant) | Mar 4, 2025 | 100,400 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Janus Henderson Group PLC | 7.57% | 7,429,718 | 160.78M | Sep 29, 2025 |
| Blackrock Inc. | 7.17% | 7,041,102 | 152.37M | Dec 30, 2025 |
| Vanguard Group Inc | 5.98% | 5,864,781 | 126.91M | Dec 30, 2025 |
| Gendell, Jeffrey L. | 5.41% | 5,314,810 | 115.01M | Sep 29, 2025 |
| Polar Capital Holdings PLC | 4.07% | 3,999,338 | 86.55M | Sep 29, 2025 |
| Vivo Capital, LLC | 2.73% | 2,684,109 | 58.08M | Sep 29, 2025 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.93% | 2,874,464 | 62.20M | Sep 29, 2025 |
| iShares Trust-iShares Russell 2000 ETF | 2.30% | 2,255,170 | 48.80M | Dec 30, 2025 |
| JANUS INVESTMENT FUND-Janus Henderson Global Life Sciences Fund | 1.53% | 1,503,297 | 32.53M | Sep 29, 2025 |
| JANUS INVESTMENT FUND-Janus Henderson Venture Fund | 1.47% | 1,441,349 | 31.19M | Sep 29, 2025 |
| Datum One Series Trust-BRANDES INTERNATIONAL SMALL CAP EQUITY FUND | 1.17% | 1,149,273 | 24.87M | Sep 29, 2025 |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 1.05% | 1,028,939 | 22.27M | Sep 29, 2025 |